Neoplasms News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH - AJMC.com Managed Markets Network



Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH 
AJMC.com Managed Markets Network
Several studies have also noted an increased risk of therapy-related myeloid neoplasms, Ebert noted. ?Patients with CHIP have reduced survival, partially due to therapy-related malignancies as well as the development of cardiovascular [CV] disease ...

 


Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies - Dove Medical Press



Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies 
Dove Medical Press
Abstract: Tetraspanin CD82, also known as KAI1, was revealed as an attractive prognostic tumor biomarker in recent studies. However, some results of these studies remained debatable and inconclusive. Therefore, we conducted a meta-analysis to clarify ...

 


The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life - AJMC.com Managed Markets Network



The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life 
AJMC.com Managed Markets Network
A secondary analysis presented at the 59th Annual Meeting of the American Society of Hematology found that all individual symptoms of myeloproliferative neoplasms correlate with quality of life (QoL), and having either 1 severe symptom or having ...

 


New assay may help predict which pancreatic lesions may become cancerous - Science Daily



New assay may help predict which pancreatic lesions may become cancerous 
Science Daily
"Clinicians rely on international consensus guidelines to help manage patients with pancreatic cancer precursor lesions such as intraductal papillary mucinous neoplasms (IPMNs). These guidelines are useful but pancreatic imaging does not provide ...

 


PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ... - Markets Insider



PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ... 
Markets Insider
PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other ...

and more » 


Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms - Dove Medical Press



Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms 
Dove Medical Press
Objective: Primary myelofibrosis (PMF) is one of the Philadelphia negative myeloproliferative neoplasms (MPN). The main clinical features are obvious physical symptoms and symptomatic splenomegaly. It may be converse to leukemia and has a shortened ...

 


Plasma Cell Neoplasm Treatment Market report 2017 ? 2025: By Treatment Type, Disease Indication, End User, by ... - MilTech



Plasma Cell Neoplasm Treatment Market report 2017 ? 2025: By Treatment Type, Disease Indication, End User, by ... 
MilTech
Continuous development of new therapies by the pharmaceutical companies and development of biologics treatment options are also expected to boost the growth of the plasma cell neoplasm treatment market. Increasing development of generics & biosimilars ...

and more » 


Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic ... - Healio



Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic ... 
Healio
ATLANTA ? Immunosuppressive therapy helped nearly 40% of patients with myelodysplastic syndrome achieve transfusion independence, according to study results presented at ASH Annual Meeting and Exposition. Patients who achieved response or transfusion ...

 


Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting - Nasdaq



Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting 
Nasdaq
Stemline is developing three clinical stage product candidates: SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), a cell surface receptor expressed on a variety of malignancies including blastic ...

and more » 


Blueprint Medicines (BPMC) Reports New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in ... - StreetInsider.com



Blueprint Medicines (BPMC) Reports New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in ... 
StreetInsider.com
As of the data cutoff date of October 4, 2017, the data showed an overall response rate (ORR) of 72 percent and a disease control rate (DCR) of 100 percent in patients evaluable for response, based on the International Working Group-Myeloproliferative ...

and more »